Pharmacological blockade of TLR4 activity prevented NASH fEV‐induced endothelial permeability and the transmigration of monocytes suggesting that fEVs activate the TLR4 pathway. Here, TLR4 is linked to metabolic dysfunction-associated steatohepatitis.